Stock Events

Stock Events

Gabather 

0
0
+SEK0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27NovExpected
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
0
0.33
0.67
1
Expected EPS
0
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-4.65MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN.ST
Mkt Cap2.59T
AstraZeneca operates in the biopharmaceutical sector focusing on various therapeutic areas, including neuroscience, which overlaps with Gabather's focus on CNS disorders.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on developing therapies for neurological diseases, directly competing with Gabather's CNS drug development.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has a strong portfolio in neuroscience, including treatments for psychiatric and neurodegenerative conditions, similar to Gabather's target market.
Novartis
NVS
Mkt Cap292.35B
Novartis offers drugs for neurological conditions, directly competing with Gabather in the CNS pharmaceutical market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a diversified portfolio that includes treatments for neurological disorders, positioning it as a competitor in the CNS space.
Merck
MRK
Mkt Cap366B
Merck produces medications for health disorders including neurologic conditions, competing with Gabather's CNS focus.
GSK
GSK.LSE
Mkt Cap78.89B
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical specializes in generic and specialty medicines, including CNS treatments, competing with Gabather's market.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for CNS disorders, aligning as a competitor in the same therapeutic area as Gabather.

About

Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disorders, pain relief, and cognitive function enhancement, notably those related to Alzheimer's disease. Founded in 2014, its operations are headquartered in Södertälje, Sweden.
Show more...
CEO
Michael-Robin Witt
Employees
2
Country
Sweden
ISIN
SE0024171961

Listings

MU
DE
5J2.MU
ST
SE
GABA-BT-UN.ST
F
DE
5J2.F
ST
SE
GABA.ST

0 Comments

Share your thoughts

FAQ

What is Gabather stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Gabather stocks are traded under the ticker GABA-BT-UN.ST.
When is the next Gabather earnings date?▼
Gabather is going to release the next earnings report on November 27, 2026.
What were Gabather earnings last quarter?▼
GABA-BT-UN.ST earnings for the last quarter are 0 SEK per share, whereas the estimation was 0 SEK resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A SEK per share.
What is Gabather revenue for the last year?▼
Gabather revenue for the last year amounts to 0 SEK.
What is Gabather net income for the last year?▼
GABA-BT-UN.ST net income for the last year is -4.65M SEK.
How many employees does Gabather have?▼
As of September 04, 2026, the company has 2 employees.
In which sector is Gabather located?▼
Gabather operates in the Health & Wellness sector.
When did Gabather complete a stock split?▼
Gabather has not had any recent stock splits.
Where is Gabather headquartered?▼
Gabather is headquartered in Södertälje, Sweden.